Clinical assessment of Navauppu Mezhugu for Painful menstruation.
Phase 3
- Conditions
- Health Condition 1: N946- Dysmenorrhea, unspecified
- Registration Number
- CTRI/2023/02/049786
- Lead Sponsor
- Dr Megganah
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Women in the age group between 11 to 25 years
Onset of pain within 6-12 hours after the onset of menses
Nulliparous women
Cramping or pain in the lower abdomen
Pelvic pain
Low back pain
Pain spreading down the legs.
Patient willing to sign the informed consent.
Exclusion Criteria
Presence of any pelvic pathology such as chronic pelvic infection, pelvic
endometriosis, adenomyosis, uterine fibroid and endometrial polyp
Presence of any associated severe systemic illness
Uterine or cervical polyp
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Significance reduction in clinical symptom assessed by using WaLIDD score.Timepoint: 6 Months
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms and drug targets does Navauppu Mezhugu modulate in primary dysmenorrhea?
How does Navauppu Mezhugu compare to NSAIDs and hormonal contraceptives in treating primary dysmenorrhea efficacy?
What biomarkers are associated with Navauppu Mezhugu efficacy in CTRI/2023/02/049786 primary dysmenorrhea trial?
What are the potential adverse events and management strategies for Navauppu Mezhugu in dysmenorrhea trials?
Are there related herbal compounds or combination therapies to Navauppu Mezhugu for primary dysmenorrhea?